行情

XOMA

XOMA

标记临床研究
NASDAQ

实时行情|Nasdaq Last Sale

27.66
-1.05
-3.66%
盘后: 27.66 0 0.00% 16:00 02/21 EST
开盘
28.53
昨收
28.71
最高
28.53
最低
27.55
成交量
2.82万
成交额
--
52周最高
28.85
52周最低
11.58
市值
2.42亿
市盈率(TTM)
-237.2213
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XOMA价格均价为45.00,最高价位80.00,最低价为25.00。

EPS

XOMA 新闻

更多
  • Before You Buy XOMA Corporation (NASDAQ:XOMA), Consider Its Volatility
  • Simply Wall St. · 01/22 18:02
  • 多国航线避飞两伊 绕远路成本猛涨
  • 新华网 · 01/11 01:49
  • 雪上加霜!OYO被称将在中国和印度裁员数千人
  • 新浪科技 · 01/11 01:23
  • 一天狂跌20%不要怕 Jim Cramer :大胆买入!
  • 新浪财经综合 · 01/11 01:10

所属板块

生物技术和医学研究
+0.06%
制药与医学研究
+0.70%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

XOMA 简况

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
展开

微牛提供XOMA Corp(NASDAQ-XOMA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XOMA股票新闻,以帮助您做出投资决策。